Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter, Ph 3 [Phase 3] Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG

NCT02449239 is registered in ClinicalTrials.gov with Sesen Bio, Inc. as lead sponsor.

NCT NCT02449239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02449239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter, Ph 3 [Phase 3] Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG
Lead sponsor
Sesen Bio, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2015
Completion date
May 31, 2022
Enrollment
133 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer